ASCO: New Novartis data show Piqray efficacy in HR+/HER2- metastatic breast cancer

Swiss pharma giant Novartis (NOVN: VX) on Friday announced results of an exploratory retrospective biomarker analysis finding that different genetic mutation profiles in tumors harboring PIK3CA mutation did not affect treatment benefit with Piqray (alpelisib) plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.

Selected as an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, the retrospective analysis of data from the Phase III SOLAR-1 study found that the clinical benefit of the Piqray and fulvestrant combination was maintained regardless of genetic alterations in most biomarkers, including ESR1 and genes implicated in resistance to CDK4/6 inhibitors1.

“This analysis evaluating alpelisib and fulvestrant across HR+/HER2- advanced breast cancer tumors with different genetic alterations confirms the importance of using alpelisib to selectively target PIK3CA as a major oncogenic driver in these tumors,” said Dr Dejan Juric, director, Termeer Center for Target Therapies, Mass  SaveGeneral Cancer Center in Boston.